

**NOVO**  
—SINCE 1946—



**2X**

Confidence


**NEXIPOX** **PLUS**<sup>®</sup>

Be **2X** Sure with **Trehalose Protection**

**INDIAN CLINICAL TRIAL**  
**424 SUBJECTS**

• **SEROCONVERSION** • **IMMUNOGENICITY** • **SAFETY**

## NEXIPOX PLUS® OFFERS SUPERIOR IMMUNESHIELD (GMFR)



Abbreviation: GMFR-Geometric Mean Fold Rise  
Reference: Data on File.

- **NEXIPOX PLUS®** demonstrated a notable increase in fold rise in anti-varicella IgG antibodies, indicating strong immune amplification post-vaccination.
- In children (1–12 years), **NEXIPOX PLUS®** achieved a **35.4x** higher GMFR compared to International Brand.

## NEXIPOX PLUS® DELIVERS ROBUST ANTIBODY GEOMETRIC MEAN TITERS

Cohort	Time Point	NEXIPOX PLUS®	International Brand	P Value
Children (1-12 years) Single dose	Pre Dose	20.78 ± 3.43 [20.20:21.55]	27.71 ± 4.29 [26.8:28.56]	0.19
	Post Dose	738.05 ± 3.91 [737.28:739.0]	698.76 ± 3.95 [697.9:700.1]	0.92

- **NEXIPOX PLUS®** induced a marked rise in antibody GMTs post-vaccination, demonstrating a strong immune response against varicella virus.
- The **GMT increased significantly to 738.05 mIU/mL** for **NEXIPOX PLUS®** and 698.76 mIU/mL for International Brand.

# NEXIPOX **PLUS**<sup>®</sup>


Be **2X** Sure with **Trehalose Protection**

## NEXIPOX PLUS<sup>®</sup> DELIVERS HIGHEST SEROCONVERSION

Cohort	Vaccine Group	Number of subjects vaccinated	Seronegative (Excluding seropositive; pre-vaccination $\leq 10$ mIU/ml)	Responders (post-vaccination $> 10$ mIU/ml)	Seroconversion rate (responders/seronegative)	Difference in SCR*	P Value
Children (1-12 years) Single dose	NEXIPOX PLUS <sup>®</sup>	100	57	56	98.24% [90.60:99.95]	-2.41 [-9.01:4.18]	0.47
	International Brand	100	48	46	95.83% [85.74:99.49]		

- **NEXIPOX PLUS<sup>®</sup>** consistently achieved **highest seroconversion rate of 98.2% in children.**
- **NEXIPOX PLUS<sup>®</sup>** elicited strong and reliable immune response.

## NEXIPOX PLUS<sup>®</sup> DELIVERS A STRONG AND CONSISTENT FOLD RISE



- The  $\geq 4$ -fold seroconversion rate (SCR)\* at 6 weeks post-vaccination was **91%** with **NEXIPOX PLUS<sup>®</sup>** and **89%** with International Brand.

\*SCR-Seroconversion Rate

## NEXIPOX PLUS® SHOWED SUPERIOR SAFETY

### Summary of Adverse Events Reported in the Study

Total No. of Subjects	N (%) [No. of Subjects Reported]
424	106 (20.75%) [88]
<b>NEXIPOX PLUS® (n=212)</b>	
Any Adverse Events (AEs)	52 (20.28%) [43]
Any Serious Adverse Events (SAEs)	[0]
<b>International Brand (n=212)</b>	
Any Adverse Events (AEs)	54 (21.22%) [45]
Any Serious Adverse Events (SAEs)	1 (0.47%) [1]

**NEXIPOX PLUS®** showed superior safety, with **no serious adverse events** compared to the International Brand, which reported 1 serious adverse event of URTI requiring hospitalisation.

## SOLICITED LOCAL AND SYSTEMIC ADVERSE EVENTS

Adverse Event Term	NEXIPOX PLUS® (N=212)*	International Brand (N=212)*	P-Value
Local Solicited Adverse Events			
Pain at injection site	23 (10.8%)	25 (11.7%)	0.77
Redness at injection site	12 (5.6%)	11 (5.1%)	0.83
Swelling	05 (2.3%)	06 (2.8%)	0.76
Rash at injection site	01 (0.4%)	01 (0.4%)	>0.999
Systemic Solicited Adverse Events			
Fever	05 (2.3%)	06 (2.8%)	0.76
Rash	00 (0%)	00 (0%)	

No significant difference was observed between the occurrence, severity, or causality of adverse events between **NEXIPOX PLUS®** and International Brand.

**Gelatin-Free NEXIPOX PLUS®** has higher safety in terms of anaphylactic reaction, when compared to International Brand.

# 2X

# NEXIPOX **PLUS**<sup>®</sup>

Be **2X** Sure with **Trehalose Protection**



## Clinical Study Overview



**Study Type:**  
Comparative clinical study



**Comparator:**  
International Brand



**Subjects:**  
424 participants



## Immunogenicity



**Seroconversion Rate**




**Geometric Mean Fold Rise (GMFR)**



**4-Fold Seroconversion Rate**



**Geometric Mean Titre (GMT)**



## Safety



**Adverse Event Monitoring**



When it comes to Chickenpox Prevention

**NOVO**  
—SINCE 1946—

Be

**2X**

**Confident**

With

**NEXIPOX** **PLUS**<sup>®</sup>

Be **2X** Sure with **Trehalose Protection**



**Trehalose Protection:**  
Safeguards viral potency  
for consistent protection



**Unmatched Stability:**  
Thermostable up to 4 weeks  
at room temperature



**Reliable Safety:**  
The highest protection with  
no serious adverse events




**Robust Immunity:**  
Consistent and highest  
seroconversion rate of 98.2%



**Better Protection:**  
Superior immune shield  
against chickenpox with  
35.4x GMFR



**Zero Breakthrough:**  
After two doses



**NOVO Medi Sciences Pvt. Ltd.**  
—Your Most Trusted Partner Since 1946—